Meeting
2018 Gastrointestinal Cancers Symposium
A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).
Authors
Lipika Goyal
Massachusetts General Hospital/ Harvard Medical School, Boston, MA
Lipika Goyal , Hui Zheng , Thomas Adam Abrams , Rebecca A. Miksad , Andrea J. Bullock , Jill N. Allen , Matthew B. Yurgelun , Susan Sheehan , Patricia Lynch , Anthony James Afflitto , Caroline Dinicola , Jordan Robert Maurer , Stephanie Reyes , Michelle Knowles , Aralee Galway , Jeffrey W. Clark , Emilie Birnbaum , Anna Khachatryan , Gabriel Dan Duda , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01775501
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 270)
DOI
10.1200/JCO.2018.36.4_suppl.270
Abstract #
270
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.
First Author: Danni Li
Poster
2021 ASCO Annual Meeting
A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).
First Author: MinKe He
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2013 ASCO Annual Meeting
Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).
First Author: Eric Assenat